Timely diagnosis makes a difference.

Symptomatic severe aortic stenosis (ssAS) may be difficult to diagnose, especially among women, but the risks of it going untreated are too high to live with.6


Exclamation icon Indications, Safety, and Warnings
Woman

The undertreatment of aortic stenosis (AS) is estimated to be

~49%
nationally†13-22

Why does aortic stenosis go untreated?


The incidence of untreated ssAS remains high due to  the following factors:

  • Patients do not recognize or report their symptoms.23
  • Heart murmurs are undetected.24
  • Echo findings are misclassified due to complex cardiac anatomy.24
  • Referrals are delayed or too late.24

If treatment is delayed, the benefits of TAVR decline25

Why are women more challenging to diagnose?


AS pathophysiology and symptoms appear differently by sex,3,4,5 making it more challenging to achieve an early diagnosis and timely treatment:


Aortic Stenosis Pathophysiology & Symptomology4


WOMEN MEN
Clinical presentation Shortness of breath, dizziness, syncope, fatigue Angina
Older Younger
More advanced heart failure symptoms Less advanced heart failure symptoms
Pathophysiology Fibrocalcific aortic stenosis, less aortic valve calcification Calcific aortic stenosis, more aortic valve calcification
Concentric hypertrophy Eccentric hypertrophy
Paradoxical low flow/low gradient AS High gradient or classical low flow/low gradient
Anatomy Smaller annulus Larger annulus

TAVR risks may include, but are not limited to, death, stroke, damage to the arteries, bleeding, and need for permanent pacemaker.

™* Third-party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company.

† Evolut TAVR is indicated to treat patients who have been diagnosed with symptomatic severe aortic stenosis.

‡ Based on the 1 year follow-up results from the SMART clinical trial which showed differences in valve performance for Evolut compared to SAPIEN and no differences in safety outcomes. SMART primarily studied small annulus patients, predominantly women.8

§ Better blood flow, or "near-normal transvalvular flow" means that your new heart is operating well and the gradient across your valve is < 20 mmHg%


  1. Herrmann HC, Mehran R, Blackman DJ, et al. Self-Expanding or Balloon-Expandable TAVR in Patients with a Small Aortic Annulus. N Engl J Med. June 6 2024;390(21):1959–1971
  2. Ross J Jr, Braunwald E. Aortic stenosis. Circulation. July 1968;38(1 Suppl):61-67. 
  3. Nau DP , Ellis JJ , Kline-Rogers EM, Mallya U, Eagle KA, Erickson SR. Gender and perceived severity of cardiac disease: evidence that women are “tougher.” Am J Med. November 2005;118(11):1256–1261.
  4. Iribarren AC, AlBadri A, Wei J, et al. Sex differences in aortic stenosis: Identification of knowledge gaps for sex-specific personalized medicine. Am Heart J Plus. September 2022;21:100197. 
  5. Tribouilloy C, Bohbot Y, Rusinaru D, et al. Excess Mortality and Undertreatment of Women With Severe Aortic Stenosis. J Am Heart Assoc. January 5, 2021;10(1):e018816 
  6. Julia Stehli, Rozanne Johnston, Stephen J Duffy, Sarah Zaman, Tomoe D H Gusberti, Misha Dagan, Dion Stub, Antony Walton, Waiting times of women vs. men undergoing transcatheter aortic valve implantation, European Heart Journal - Quality of Care and Clinical Outcomes, Volume 9, Issue 7, November 2023, Pages 691–698.
  7. Rice CT, Barnett S, O’Connell SP, et al. Impact of gender, ethnicity and social deprivation on access to surgical or transcatheter aortic valve replacement in aortic stenosis: a retrospective database study in England. Open Heart. September 2023;10(2):e002373.
  8. Tchétché D, Mehran R, Blackman DJ, et al. Transcatheter Aortic Valve Implantation by Valve Type in Women With Small Annuli: Results From the SMART Randomized Clinical Trial. JAMA Cardiol. Published online October 9, 2024.
  9. Yakubov SJ, Van Mieghem NM, Oh JK, Ito S, Grubb KJ, O’Hair D, Forrest JK, Gada H, Mumtaz M, Deeb GM, Tang GHL, Rovin JD, Jain R, Windecker S, Skelding KA, Kleiman NS, Chetcuti SJ, Dedrick A, Boatman SV, Popma JJ, Reardon MJ, Impact of Transcatheter or Surgical Aortic Valve Performance on 5-Year Outcomes in Patients at ≥ Intermediate Risk, Journal of the American College of Cardiology (2025), doi: https://doi.org/10.1016/j.jacc.2025.02.009.
  10. Reardon M, et al. Transcatheter Versus Surgical Aortic Valve Replacement in Aortic Stenosis Patients at Low Surgical Risk: 4-Year Outcomes from the Evolut Low Risk Trial. Presented at TCT; October 2023.
  11. Medtronic computational data model on file compared to the Evolut platform. Bench top computational model may not be indicative of clinical performance. Evolut FX+ Test Report: DO1106198 Rev. A.
  12. Adams DH, et al. Transcatheter Aortic-Valve Replacement with a Self-Expanding Prothesis. N Engl J Med. 2014;370:1790-1798
  13. STS Adult Cardiac Database. 2010 Harvest, Isolated AVR.
  14. Bach DS, Cimino N, Deeb GM. Unoperated patients with severe aortic stenosis. J Am Coll Cardiol. 2007 Nov 13;50(20):2018-9. doi: 10.1016/j.jacc.2007.08.011. Epub 2007 Oct 29. PMID: 17996571.
  15. Pellikka PA, Sarano ME, Nishimura RA, Malouf JF, Bailey KR, Scott CG, Barnes ME, Tajik AJ. Outcome of 622 adults with asymptomatic, hemodynamically significant aortic stenosis during prolonged follow-up. Circulation. 2005 Jun 21;111(24):3290-5. doi: 10.1161/CIRCULATIONAHA.104.495903. Epub 2005 Jun 13. PMID: 15956131.
  16. Charlson E, Legedza AT, Hamel MB. Decision-making and outcomes in severe symptomatic aortic stenosis. J Heart Valve Dis. 2006 May;15(3):312-21. PMID: 16784066.
  17. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet. 2006 Sep 16;368(9540):1005-11. doi: 10.1016/S0140-6736(06)69208-8. PMID: 16980116.
  18. Lindroos M, Kupari M, Heikkilä J, Tilvis R. Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. J Am Coll Cardiol. 1993 Apr;21(5):1220-5. doi: 10.1016/0735-1097(93)90249-z. PMID: 8459080.
  19. Mack MJ, Brennan JM, Brindis R, et al. Outcomes Following Transcatheter Aortic Valve Replacement in the United States. JAMA. 2013;310(19):2069–2077. doi:10.1001/jama.2013.282043
  20. Medtronic data on file.
  21. Lung B, Baron G, Butchart EG, Delahaye F, Gohlke-Bärwolf C, Levang OW, Tornos P, Vanoverschelde JL, Vermeer F, Boersma E, Ravaud P, Vahanian A. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur Heart J. 2003 Jul;24(13):1231-43. doi: 10.1016/s0195-668x(03)00201-x. PMID: 12831818.
  22. Bavaria JE. TAVR Update: New Insights and Perspectives from the U.S. National STS/ACC TVT Registry. Available from STS National Database.
  23. McCarthy CP, et al. Cleve Clin J Med. 2016;83:271-280
  24. Brennan J, Leon MB, Sheridan P, Boero IJ, Chen Q, Lowenstern A, Thourani V, Vemulapalli S, Thomas K, Wang TY, Peterson ED. Racial Differences in the Use of Aortic Valve Replacement for Treatment of Symptomatic Severe Aortic Valve Stenosis in the Transcatheter Aortic Valve Replacement Era. J Am Heart Assoc. 2020 Aug 18;9(16):e015879. doi: 10.1161/JAHA.119.015879. Epub 2020 Aug 11. PMID: 32777969; PMCID: PMC7660794.
  25. Wijeysundera HC, et al. Impact of wait times on the effectiveness of transcatheter aortic valve replacement in severe aortic valve disease: a discrete event simulation model Can J Cardiol. 2014;30:1162–1169.
  26. Medtronic internal data on file.
  27. Kornyeva A, Burri M, Lange R, Ruge H. Self-expanding vs. balloon-expandable transcatheter heart valves in small aortic annuli. Front Cardiovasc Med. August 3, 2023;10:1175246.
  28. Forrest JK, Deeb GM, Yakubov SJ, et al. 4-Year Outcomes of Patients With Aortic Stenosis in the Evolut Low Risk Trial. JACC. October 24, 2023;S0735–1097(23):07628–07633. 
  29. Stanova V, Rieu R, Thollon L, et al. Leaflet Mechanical Stress in Different Designs and Generations of Transcatheter Aortic Valves: An In Vitro Study. Struct Heart. December 19, 2023;8(2):100262.